Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353746 | 0.83 | RAB9A (0.35) | NPC1RAB9AMAPTGAAHTT | |
| SCHEMBL312106 | 0.80 | ALDH1A1 (0.38) | NPC1RAB9AMAPTGAAHTT | |
| SCHEMBL344237 | 0.78 | LMNA (0.33) | RAB9AMAPTAMY1AHTTLMNA | |
| SCHEMBL1637752 | 0.78 | GAA (0.43) | NPC1RAB9AMAPTGAAMAPK1 | |
| SCHEMBL1636127 | 0.77 | ACHE (0.33) | NPC1MAPTGAALMNATAAR1 | |
| SCHEMBL7255898 | 0.77 | ACHE (0.33) | RAB9AMAPTAMY1AHTTLMNA | |
| SCHEMBL1636803 | 0.77 | TUBB1 (0.33) | RAB9AMAPTAMY1AHTTLMNA | |
| SCHEMBL1637015 | 0.75 | POLB (0.33) | RAB9AMAPTAMY1AHTTLMNA | |
| SCHEMBL7959656 | 0.75 | MAOB (0.42) | RAB9AMAPTHTTLMNAMAPK1 | |
| SCHEMBL28821414 | 0.75 | POLB (0.38) | MAPTTAAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073282-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | claimed |
| US-7442792-B2 | halogenation of pyrazolo[1,5-a][1,3,5]triazin-4-ol's, with phosphorus oxyhalides, then dehalogenation and amination to yield dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine's, used as corticotropin releasing factor (CRF) receptor antagonists; anxiolytic agents; antidepressants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-10-28 | — | — | US | claimed |
| US-20070161790-A1 | Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2007-07-12 | — | — | US | claimed |
| US-7208596-B2 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-24 | — | — | US | claimed |
| EP-1706408-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5- A] -1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | claimed |
| US-20050143380-A1 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-06-30 | — | — | US | claimed |
| WO-2005051954-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2024073282-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | disclosed |
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8008232-B2 | Such as N-(3',4'-dichlorobiphenyl-2-yl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-carboxamide; seeds | BASF AKTIENGESELLSCHAFT (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-6162765-A | Substituted N-aryl nitrogen-containing heterocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-19 | — | — | US | disclosed |
| WO-2000059907-A2 | PYRAZOLOTRIAZINES AS CRF ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059908-A2 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0797573-A1 | 3-ARYL-1,2,4-TRIAZOLE DERIVATIVES WITH HERBICIDAL PROPERTIES | BAYER AG (DE) | 1997-10-01 | — | — | EP | disclosed |
| WO-1997026248-A1 | SUBSTITUTED N-ARYL NITROGEN HETEROCYCLIC COMPOUNDS AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997005117-A1 | SUBSTITUTED 1-PHENYLURACIL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996018618-A1 | 3-ARYL-1,2,4-TRIAZOLE DERIVATIVES WITH HERBICIDAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | NPC1 1757/4885RAB9A 2375/4885MAPT 2427/4885 |
| US-20070161790-A1 | Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | CRHR1, CRH, CRHR2 | NPC1 2959/4885RAB9A 2156/4885MAPT 3129/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | NPC1 1850/4885RAB9A 2117/4885MAPT 2514/4885 |
| US-20050143380-A1 | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof | CRHR1, CRH, CRHR2 | NPC1 2910/4885RAB9A 2119/4885MAPT 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.